Storm Therapeutics
9 known investors
Find your way into Storm Therapeutics
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology. Its therapies address cancer, inflammation, viral infections, and CNS diseases.
Investors · 9
Cambridge Innovation CapitalCambridge · $127K – $12.7M
Fast Track InitiativeTokyo · $1.2M – $184M
M VenturesLos Angeles · $10.8M
Pfizer Venture Investments$5M – $20M
Seroba Life SciencesDublin · $540K – $7.6M
Taiho Ventures, LLCMenlo Park
UTokyo Innovation Platform Co. Ltd.Tokyo
Pfizer Venturesreported
Also in the syndicate · 1
IP Group
Funding
SEC filings, press & company announcements$56M disclosed across 1 round · 2026
- $56Mseries CApr 2026 · 2 sources
Fast Track Initiative, IP Group, M Ventures, Pfizer Ventures, Taiho Ventures, UTokyo Innovation Platform
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 4
by search overlap
Alnylam12 shared keywordsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
Orna12 shared keywordsOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Shape Therapeutics11 shared keywordsShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
Transcode Therapeutics10 shared keywordsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Companies competing with Storm Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Storm Therapeutics do?
- STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology. Its therapies address cancer, inflammation, viral infections, and CNS diseases.
- Who are Storm Therapeutics's investors?
- Storm Therapeutics's investors include Cambridge Innovation Capital, Fast Track Initiative, M Ventures, Pfizer Venture Investments, Seroba Life Sciences, Taiho Ventures, LLC, UTokyo Innovation Platform Co. Ltd., Pfizer Ventures.
- How much funding has Storm Therapeutics raised?
- Storm Therapeutics has disclosed $56M raised across 1 round.